The mammalian target of rapamycin (mTOR) plays a key role in regulation of cellular metabolism, growth, and proliferation. The frequent hyperactivation of mTOR signaling makes it an attractive target for therapeutic intervention and has driven the development of a number of mTOR inhibitors. Encouraging data from preclinical studies have resulted in initiation of multiple clinical trials. Furthermore, combinational strategies are being studied in an effort to overcome resistance and enhance efficacy. Although additional studies are required to determine their specific role in the clinical setting, mTOR inhibitors remain a promising therapeutic option for the treatment of cancer.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalCancer Letters
Issue number1
StatePublished - Jun 1 2012


  • Cancer
  • Cancer therapy
  • Drug resistance
  • MTOR

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'MTOR inhibitors in cancer therapy'. Together they form a unique fingerprint.

Cite this